← Eichor
Study identifier: NCT05212792 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Genomics and COVID-19 Vaccine Adverse Events

Condition: Vaccine Adverse Reaction  ·  Sponsor: University of British Columbia

PhaseN/A
Planned participants6325
Who can joinAll sexes, 5 Years to 99 Years
Healthy volunteersYes

About this study

Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis, after COVID-19 vaccination have been reported worldwide. Study hypothesis: there are genetic factors that contribute to increased risks of particular COVID-19 vaccine-induced adverse events. The objective of the study is to determine if there are specific genetic factors strongly associated with each of the COVID-19 vaccine-induced adverse events (i.e., GBS, VITT/TTS, and myocarditis/pericarditis).

This description comes directly from the study's public registry record.

Talk to the study team

Bruce Carleton, PharmD  ·  1.877.878.4131  ·  bcarleton@popi.ubc.ca

Always discuss trial participation with your own doctor first.

Locations (1)

British Columbia Children's Hospital Research InstituteVancouver, British Columbia, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05212792